Reven Announces New Chief Operating Officer

WESTMINSTER, Colo.–(BUSINESS WIRE)–Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders, today announced that Brian Denomme, Co-Founder, previously Reven’s Chief Operating Officer will be stepping into a full-time role as the company’s President. In addition, the company is pleased to announce the appointment of Daniel Hoffman as Chief Operating Officer, effective immediately. Mr. Hoffman will support co-founders Peter Lange, Michael Volk, and Brian Denomme in executing their vision in bringing the company’s flagship platform drug Rejuveinix (RJX) to market.

As President, Mr. Denomme’s wealth of knowledge and experience in international business, including co-founding Reven, will provide leadership and oversight to the management team. In his role, he will focus on expanding the company’s growth through business development, acquisitions, and investor relations.

“I am incredibly energized to lead the company to its next phase of business development. As part of our company’s continued growth, I am equally excited to work with Dan and help him transition into the role as our new COO. I have tremendous confidence in Dan’s ability to help take Reven to the next level, ensuring best practices and operational excellence across the company,” said Denomme.

Mr. Hoffman brings with him more than two decades of top Fortune 100 corporate executive experience, having held numerous executive and operational leadership roles. Most recently, as Chief of Design for a medical device company where he launched the company’s flagship product. In his role, he helped successfully negotiate multiple licensing deals with two of the largest pharmaceutical companies. Mr. Hoffman previously served as Executive Creative Director for CNBC Business News, where he created and developed new programming for the network. He has a proven track record of success; as a nationally recognized award-winning producer, he transformed strategy into reality to achieve organizational objectives. Additionally, Mr. Hoffman led numerous shows’ branding and production development, most notably CNBC’s Mad Money with Jim Cramer, Fast Money and Options Action.

Hoffman said, “As COVID-19 remains at the vanguard impacting everyone’s lives, I’m honored to be a part of a team that is passionate in developing a novel platform drug that will improve people’s lives worldwide and provide a much-needed solution to our most vulnerable patients.”

Mr. Hoffman’s corporate executive experience, development, and leadership will enhance the range and scope of the company’s growth and goal to get RJX to market. Furthermore, Mr. Hoffman demonstrates all the qualities necessary to assume management of the company’s daily corporate operations and brand development.

About Rejuveinix (RJX)

RJX is an intravenous (IV) formulation of known physiologically compatible compounds that is being developed for more effective supportive therapy of patients with sepsis, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS). RJX is a proprietary composition of naturally occurring antioxidants and anti-inflammatory agents which, in combination, provide potent and immediate tissue protection. The components of RJX exhibited promising activity in clinical studies involving ARDS patients and/or non-clinical studies in animal models of ARDS. The published data from these clinical and non-clinical studies provided the medical-scientific rationale for Reven’s clinical development strategy for RJX and a clinical study in COVID-19 patients. The clinical tolerability of RJX was confirmed in a recently completed double blind, placebo-controlled Phase 1 dose-escalation study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105).

About Reven Holdings, Inc.

Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado based operating company Reven, LLC, is a biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.

Reven’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “on-track”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the company’s periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information regarding future events, or otherwise.

Contacts

Michael Volk at [email protected]